Inhibition of terminal complement complex formation alleviates murine antibody-mediated TRALI

D Dawei Chen (State Key Laboratory of Chemo and Biosensing, College of Chemistry and Chemical Engineering, Advanced Catalytic Engineering Research Center of the Ministry of Education) H Huaqin Liang (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) X Xiuzhang Xu (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) W Wenjie Xia X Xin Ye Y Yalin Luo (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) J Jiansen He (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) Y Yaori Xu (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) J Jing Liu H Hui Ren S Shengxue Luo (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) T Trent M. Woodruff W Wioleta M. Zelek (4Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom) B B. Paul Morgan (4Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom) R Rick Kapur (Sanquin Blood Supply Foundation) S Sentot Santoso (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China) Y Yongshui Fu (1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China)

Abstract

Abstract Transfusion-related acute lung injury (TRALI) is a leading cause of blood transfusion–triggered mortality. Recently, we demonstrated the critical role of Fc-dependent complement activation in anti-CD36–mediated murine TRALI. In this study, we found that C5−/− mice were protected, and administration of anti-C5 rescued wild-type mice from anti-CD36–mediated TRALI. However, C5aR1−/− mice were not protected against anti-CD36–mediated TRALI, implying a possible role of C5b-9 (membrane attack complex [MAC]). Accordingly, elevated levels of MAC were detected in bronchoalveolar lavage fluid and lung tissue of mice with anti-CD36–induced TRALI. Inhibition of MAC formation by administration of anti-C7–blocking monoclonal antibody alleviated TRALI in mice, suggesting the critical role of the MAC in the pathology of anti-CD36–mediated TRALI. Furthermore, anti-C7 treatment also led to favorable outcome in murine TRALI induced by anti–major histocompatibility complex class 1, indicating the potential broader applicability of MAC inhibitors in the treatment of antibody-mediated TRALI. Therefore, this approach may be promising to further explore the treatment of patients with TRALI.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 6
Published August 07, 2025
Pages 759-764
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (17)

D

Dawei Chen

State Key Laboratory of Chemo and Biosensing, College of Chemistry and Chemical Engineering, Advanced Catalytic Engineering Research Center of the Ministry of Education

H

Huaqin Liang

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

X

Xiuzhang Xu

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

W

Wenjie Xia

X

Xin Ye

Y

Yalin Luo

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

J

Jiansen He

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

Y

Yaori Xu

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

J

Jing Liu

H

Hui Ren

S

Shengxue Luo

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

T

Trent M. Woodruff

W

Wioleta M. Zelek

4Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom

B

B. Paul Morgan

4Dementia Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom

R

Rick Kapur

Sanquin Blood Supply Foundation

S

Sentot Santoso

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China

Y

Yongshui Fu

1Institute of Blood Transfusion, Guangzhou Blood Centre, Guangzhou, China